단클론항체 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 제품 유형별, 용도별, 생산원별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Monoclonal Antibody Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By Production Source, By End User, By Region and Competition, 2020-2030F
단클론항체 치료제 세계 시장은 2024년에는 2,430억 2,000만 달러로 2030년에는 4,182억 8,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 9.43%의 CAGR을 기록할 것으로 예상됩니다.
최근 몇 년 동안 전 세계 헬스케어 분야는 의학 연구와 기술의 획기적인 발전으로 큰 변화를 겪고 있습니다. 그 중에서도 치료제에 있어서의 단클론항체(mAb)의 개발과 응용은 큰 주목을 받고 있습니다. 단클론항체는 다양한 질병의 치료에 혁명을 가져왔으며, 저분자 단클론항체 치료제 부문은 이 역동적인 분야에서 중요한 플레이어로 부상하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
2,430억 2,000만 달러 |
| 시장 규모 : 2030년 |
4,182억 8,000만 달러 |
| CAGR : 2025-2030년 |
9.43% |
| 급성장 부문 |
인간화 |
| 최대 시장 |
북미 |
단클론항체는 체내의 특정 단백질이나 항원을 타깃으로 설계된 바이오의약품의 일종입니다. 단클론항체는 B세포로 알려진 한 종류의 면역세포를 클론화하여 동일한 항체를 생산하게함으로써 만들어집니다. 이 항체는 암세포, 병원체, 자가면역 유발 물질의 표면에서 발견되는 분자와 같은 특정 분자와 결합하도록 설계되어 있습니다. 이러한 표적화 접근법을 통해 다양한 질병에 대한 정확한 치료가 가능합니다.
세계 저분자 단클론항체 치료제 시장은 다양한 치료 용도를 아우르며 최근 괄목할 만한 성장세를 보이고 있습니다. 암, 자가면역질환, 감염성 질환과 같은 만성질환은 여전히 세계 보건의 큰 과제이며, 단클론항체는 유망한 치료 옵션으로 부상하고 있습니다. 생명공학, 특히 항체 공학의 발전은 보다 특수하고 효과적인 단클론항체를 만들어 치료 적용 범위를 넓히고 시장 수요를 증가시키고 있습니다. 또한, 단클론항체는 개인의 유전적 체질과 질병 프로파일에 맞춰 치료하는 맞춤의료의 중심이 되어 치료 성과와 환자 만족도를 모두 향상시키고 있습니다.
각국 정부는 혁신적인 프로젝트에 대한 자금 지원과 지원을 통해 단클론항체 치료제를 포함한 바이오테크놀러지의 연구개발을 적극적으로 지원하고 있습니다. 이는 시장 성장을 가속화하는 데 있어 매우 중요합니다.
주요 시장 촉진요인
만성질환 유병률 증가
적응증 및 승인 확대
맞춤형 의료에 대한 관심 증가
바이오의약품 투자 증가
주요 시장 과제
높은 개발 비용
바이오시밀러와의 경쟁
주요 시장 동향
기술 발전
전략적 파트너십과 협업
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 단클론항체 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 제품 유형별(네이키드, 융합 단백질, 항체 단편, 접합체, 다특이성)
- 용도별(암, 자가면역질환, 감염증, 기타)
- 생산원별(인간, 인간화, 키메라, 기타)
- 최종사용자별(병원, 전문 센터, 연구기관)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 단클론항체 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 단클론항체 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 단클론항체 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 단클론항체 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 단클론항체 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
- 인수합병(있는 경우)
- 제품 발매(있는 경우)
- 최근 동향
제13장 Porter's Five Forces 분석
- 업계내 경쟁
- 신규 참여의 가능성
- 공급업체의 능력
- 고객의 능력
- 대체품의 위협
제14장 경쟁 구도
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Merck & Co. Inc.
- Pfizer Inc.
- Eli Lilly and Co.(Lilly)
- Sanofi S.A.
- AstraZeneca Plc
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- GSK Plc
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
The global monoclonal antibody therapeutics market was valued at USD 243.02 billion in 2024 and is projected to reach USD 418.28 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.43% during the forecast period. Recent years have seen a significant transformation in the global healthcare sector, driven by groundbreaking advancements in medical research and technology. Among these, the development and application of monoclonal antibodies (mAbs) in therapeutics has garnered significant attention. Monoclonal antibodies have revolutionized the treatment of various diseases, with the lower monoclonal antibody therapeutics segment emerging as a key player within this dynamic field.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 243.02 Billion |
| Market Size 2030 | USD 418.28 Billion |
| CAGR 2025-2030 | 9.43% |
| Fastest Growing Segment | Humanized |
| Largest Market | North America |
Monoclonal antibodies are a class of biopharmaceuticals designed to target specific proteins or antigens in the body. They are created by cloning a single type of immune cell, known as a B cell, to produce identical antibodies. These antibodies are engineered to bind with particular molecules, such as those found on the surface of cancer cells, pathogens, or autoimmune triggers. This targeted approach enables precise treatment for a wide array of diseases.
The global lower monoclonal antibody therapeutics market encompasses a broad spectrum of therapeutic applications and has experienced impressive growth in recent years. Chronic diseases, such as cancer, autoimmune disorders, and infectious diseases, remain a significant global health challenge, with monoclonal antibodies emerging as a promising treatment option. Advancements in biotechnology, particularly in antibody engineering, have led to the creation of more specialized and effective monoclonal antibodies, expanding the range of therapeutic applications and increasing market demand. Furthermore, monoclonal antibodies are central to personalized medicine, where treatments are tailored to an individual's genetic makeup and disease profile, improving both treatment outcomes and patient satisfaction.
Governments worldwide are actively supporting research and development in biotechnology, including monoclonal antibody therapeutics, by providing funding and support for innovative projects. This has been pivotal in accelerating market growth.
Key Market Drivers
The rising prevalence of chronic diseases has been a major driver for the global monoclonal antibody therapeutics market. Over recent years, there has been a notable increase in the prevalence of chronic diseases, including cancer, autoimmune disorders, and infectious diseases. This surge has amplified the demand for effective and advanced treatment options, spurring growth in the monoclonal antibody therapeutics market. Monoclonal antibodies, with their targeted approach, offer promising biopharmaceutical therapies for these chronic conditions.
Chronic diseases, characterized by their long-term duration and slow progression, now account for a substantial portion of the global disease burden. Contributing factors include an aging population, sedentary lifestyles, poor dietary habits, and increased exposure to risk factors such as tobacco and alcohol. Environmental, genetic, and infectious factors also play significant roles in the development of these illnesses. As the incidence of chronic diseases rises, the demand for innovative and effective treatments is more pressing than ever.
The monoclonal antibody therapeutics market has witnessed remarkable growth, driven by the increasing acceptance of these therapies in clinical practice. Pharmaceutical companies and research institutions are heavily investing in developing novel monoclonal antibody therapies for chronic diseases, resulting in a robust pipeline of potential treatments. Additionally, regulatory agencies like the U.S. Food and Drug Administration (FDA) are approving more monoclonal antibody drugs, expanding their clinical use.
Key Market Challenges
A significant challenge facing the monoclonal antibody therapeutics market is the high cost of research, development, and clinical trials. The process of discovering and designing monoclonal antibodies is both time-consuming and expensive, requiring substantial financial investment. From early-stage research to clinical trials, these therapies undergo rigorous testing to meet safety and efficacy standards set by regulatory authorities. Compliance with regulatory requirements and the extensive documentation required for approval further increases costs. These high development costs often pose a barrier to entry for smaller biotech companies, limiting their ability to introduce new therapeutic options to the market.
Additionally, continuous research efforts to improve existing therapies and develop next-generation monoclonal antibodies further strain financial resources. As a result, larger, well-funded companies tend to dominate the market, consolidating industry power among the major players.
Key Market Trends
Technological advancements have significantly propelled the growth of the monoclonal antibody therapeutics market. In recent years, progress in genomics, proteomics, and bioinformatics has revolutionized the identification of disease-related targets, enabling more accurate development of monoclonal antibody therapies. Technologies such as phage display allow rapid screening of large antibody libraries to identify the most effective candidates for therapeutic purposes.
Moreover, advancements in antibody engineering have led to the creation of humanized and fully human antibodies, minimizing the risk of immune responses and expanding the potential patient population. Innovations in bioprocessing and cell culture techniques have enhanced the scalability and efficiency of monoclonal antibody production, reducing manufacturing costs and increasing accessibility to these therapies. The development of bioconjugation techniques has further enhanced the market, enabling the creation of antibody-drug conjugates (ADCs) that show promise in treating cancer and other diseases.
Key Market Players
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Eli Lilly and Co. (Lilly)
- Sanofi S.A.
- AstraZeneca Inc.
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- GSK Plc.
Market Segmentation
The global monoclonal antibody therapeutics market is segmented as follows:
By Product Type:
- Others
- Naked
- Fusion Protein
- Antibody Fragment
- Conjugate
- Multi-specific
By Application:
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Others
By Production Source:
- Human
- Humanized
- Chimeric
- Others
By End User:
- Hospitals
- Specialty Centers
- Research Institutes
By Region:
- North America: United States, Canada, Mexico
- Europe: France, United Kingdom, Italy, Germany, Spain
- Asia-Pacific: China, India, Japan, Australia, South Korea
- South America: Brazil, Argentina, Colombia
- Middle East & Africa: South Africa, Saudi Arabia, UAE
Competitive Landscape
The report also provides a detailed analysis of the major companies in the monoclonal antibody therapeutics market, with the option for further customization based on specific business needs.
Available Customizations
TechSci Research offers the following customization options for the global monoclonal antibody therapeutics market report:
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Monoclonal Antibody Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product Type (Naked, Fusion Protein, Antibody Fragment, Conjugate, Multi-specific)
- 5.2.2. By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Others)
- 5.2.3. By Production Source (Human, Humanized, Chimeric, Others)
- 5.2.4. By End User (Hospital, Specialty Centers, Research Institutes)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map
6. North America Monoclonal Antibody Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Application
- 6.2.3. By Production Source
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Monoclonal Antibody Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product Type
- 6.3.1.2.2. By Application
- 6.3.1.2.3. By Production Source
- 6.3.1.2.4. By End User
- 6.3.2. Canada Monoclonal Antibody Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product Type
- 6.3.2.2.2. By Application
- 6.3.2.2.3. By Production Source
- 6.3.2.2.4. By End User
- 6.3.3. Mexico Monoclonal Antibody Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product Type
- 6.3.3.2.2. By Application
- 6.3.3.2.3. By Production Source
- 6.3.3.2.4. By End User
7. Europe Monoclonal Antibody Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Application
- 7.2.3. By Production Source
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Monoclonal Antibody Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product Type
- 7.3.1.2.2. By Application
- 7.3.1.2.3. By Production Source
- 7.3.1.2.4. By End User
- 7.3.2. United Kingdom Monoclonal Antibody Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product Type
- 7.3.2.2.2. By Application
- 7.3.2.2.3. By Production Source
- 7.3.2.2.4. By End User
- 7.3.3. Italy Monoclonal Antibody Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product Type
- 7.3.3.2.2. By Application
- 7.3.3.2.3. By Production Source
- 7.3.3.2.4. By End User
- 7.3.4. France Monoclonal Antibody Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product Type
- 7.3.4.2.2. By Application
- 7.3.4.2.3. By Production Source
- 7.3.4.2.4. By End User
- 7.3.5. Spain Monoclonal Antibody Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product Type
- 7.3.5.2.2. By Application
- 7.3.5.2.3. By Production Source
- 7.3.5.2.4. By End User
8. Asia-Pacific Monoclonal Antibody Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Application
- 8.2.3. By Production Source
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Monoclonal Antibody Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product Type
- 8.3.1.2.2. By Application
- 8.3.1.2.3. By Production Source
- 8.3.1.2.4. By End User
- 8.3.2. India Monoclonal Antibody Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product Type
- 8.3.2.2.2. By Application
- 8.3.2.2.3. By Production Source
- 8.3.2.2.4. By End User
- 8.3.3. Japan Monoclonal Antibody Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product Type
- 8.3.3.2.2. By Application
- 8.3.3.2.3. By Production Source
- 8.3.3.2.4. By End User
- 8.3.4. South Korea Monoclonal Antibody Therapeutics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product Type
- 8.3.4.2.2. By Application
- 8.3.4.2.3. By Production Source
- 8.3.4.2.4. By End User
- 8.3.5. Australia Monoclonal Antibody Therapeutics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product Type
- 8.3.5.2.2. By Application
- 8.3.5.2.3. By Production Source
- 8.3.5.2.4. By End User
9. South America Monoclonal Antibody Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Application
- 9.2.3. By Production Source
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Monoclonal Antibody Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product Type
- 9.3.1.2.2. By Application
- 9.3.1.2.3. By Production Source
- 9.3.1.2.4. By End User
- 9.3.2. Argentina Monoclonal Antibody Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product Type
- 9.3.2.2.2. By Application
- 9.3.2.2.3. By Production Source
- 9.3.2.2.4. By End User
- 9.3.3. Colombia Monoclonal Antibody Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product Type
- 9.3.3.2.2. By Application
- 9.3.3.2.3. By Production Source
- 9.3.3.2.4. By End User
10. Middle East and Africa Monoclonal Antibody Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Application
- 10.2.3. By Production Source
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Monoclonal Antibody Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product Type
- 10.3.1.2.2. By Application
- 10.3.1.2.3. By Production Source
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Monoclonal Antibody Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product Type
- 10.3.2.2.2. By Application
- 10.3.2.2.3. By Production Source
- 10.3.2.2.4. By End User
- 10.3.3. UAE Monoclonal Antibody Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product Type
- 10.3.3.2.2. By Application
- 10.3.3.2.3. By Production Source
- 10.3.3.2.4. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porter's Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. F. Hoffmann-La Roche Ltd
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Novartis AG
- 14.3. Merck & Co. Inc.
- 14.4. Pfizer Inc.
- 14.5. Eli Lilly and Co. (Lilly)
- 14.6. Sanofi S.A.
- 14.7. AstraZeneca Plc
- 14.8. Bayer AG
- 14.9. Regeneron Pharmaceuticals Inc.
- 14.10. GSK Plc
15. Strategic Recommendations
16. About Us & Disclaimer
